21th April 2022 | Pharma Updates

Furmecil, an anti-cancer medication commercialised by BDR Pharma

BDR Pharmaceuticals has announced the launch of Furmecil, India’s first generic for the treatment of advanced stomach cancer, which has shown good efficacy and a favourable safety profile.

FDA issued a warning to companies selling unapproved skin lightening treatments

As per FDA, the goods are unapproved medications that are not recognized as safe and effective. The FDA has received reports of serious side effects such as rashes, face swelling, and permanent skin discoloration.

Sankalp Group and Vaishali Pharma teamed up

Sankalp Lifecare, a wholly-owned subsidiary of the Sankalp Group, has opened a nutraceutical production factory in Bavla, Gujarat, in collaboration with Mumbai-based Vaishali Pharma Ltd.

Nicomac Machinery sells 1.5 percent stake in Gland Pharma via block trades

According to sources quoting the conditions of the agreement, the investor is selling 2.45 million shares in the company, or around 1.5 percent of the total outstanding shares.

Alembic received approval from USFDA to market a generic drug

Alembic Pharmaceuticals has gained approval from the US Food and Drug Administration to market lvabradine pills, which are used to treat heart failure.

Julphar's 2030 Strategy aims to achieve long-term growth

Gulf Pharmaceutical Industries (Julphar), one of the Middle East and Africa’s major pharmaceutical companies, has unveiled its Strategy 2030, which aims to accelerate transformation through sustainable growth and deliver greater value to all stakeholders.

Experts urging policymakers to cover the cost of Covid vaccine responses

Experts believe that because there is no vaccine compensation policy at the federal or state level, victims will have a difficult time obtaining compensated for vaccination-related fatalities and injuries.